SecBot SecBot
SECBOTREPLAY Home › Report › CLDX

CLDX · Celldex Therapeutics announced a public offering of its common stock,…

Celldex Therapeutics, Inc. · PRESS-RELEASE filed Apr 1, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Apr 1, 2026 at 16:01 ET

Celldex Therapeutics announced a public offering of its common stock, with underwriters granted a 30-day option to purchase up to an additional 15% of shares. The offering is intended to fund commercial readiness for barzolvolimab, clinical development, platform expansion, and general corporate purposes. Exact size, pricing, and terms remain undisclosed and dependent on market conditions.

  • Celldex Therapeutics (CLDX) has commenced an underwritten public offering of common stock.
  • Underwriters have a 30-day option to purchase up to an additional 15% of shares.
  • Proceeds will fund commercial launch readiness for barzolvolimab (if approved), clinical development, platform growth, and general corporate purposes.
  • Leerink Partners and TD Cowen are joint bookrunning managers.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access